Author/Creator: Chilton, R. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Chilton, R.

1. 4B.02: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES BLOOD PRESSURE AND MARKERS OF ARTERIAL STIFFNESS AND VASCULAR RESISTANCE IN TYPE 2 DIABETES. (June 2015)

Authors:: Chilton, R.; Tikkanen, I.; Cannon, C.P.; Crowe, S.; Hach, T.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E.
Journal:: Journal of hypertension
Issue:: Volume 33(2015)Supplement 1
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. 4B.03: EMPAGLIFLOZIN REDUCES SYSTOLIC BLOOD PRESSURE IN DIPPER AND NON-DIPPER PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION. (June 2015)

Authors:: Chilton, R.; Tikkanen, I.; Crowe, S.; Johansen, O.E.; Broedl, U.C.; Woerle, H.J.; Hach, T.
Journal:: Journal of hypertension
Issue:: Volume 33(2015)Supplement 1
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Issue 12 (9th October 2015)

Authors:: Chilton, R.; Tikkanen, I.; Cannon, C. P.; Crowe, S.; Woerle, H. J.; Broedl, U. C.; Johansen, O. E.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 17:Issue 12(2015:Dec.)
Page Start:: 1180
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Implementing health promotion programmes in schools: a realist systematic review of research and experience in the United Kingdom. (December 2015)

Authors:: Pearson, M.; Chilton, R.; Wyatt, K.; Abraham, C.; Ford, T.; Woods, HB; Anderson, R.
Journal:: Implementation science
Issue:: Volume 10:Number 1(2015)
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. PP.05.24: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES WEIGHT AND MARKERS OF VISCERAL ADIPOSITY IN TYPE 2 DIABETES. (June 2015)

Authors:: Neeland, I.J.; Mcguire, D.K.; Chilton, R.; Crowe, S.; Lund, S.S.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E.
Journal:: Journal of hypertension
Issue:: Volume 33(2015)Supplement 1
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor. Issue 5 (6th April 2016)

Authors:: DeFronzo, R. A.; Chilton, R.; Norton, L.; Clarke, G.; Ryder, R. E. J.; Abdul‐Ghani, M.
Journal:: Diabetes, obesity & metabolism
Issue:: Volume 18:Issue 5(2016)
Page Start:: 454
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗